Anastrozole (Arimidex) is a prescription aromatase inhibitor used mainly for hormone-dependent breast cancer after menopause. Selected UK prevention use is a separate indication. NHS overview.
Confidence is high in its identity and the need for receptor, menopausal-status and safety checks. The care descriptions below are attributed guidance; this review does not establish independently finance-cleared superiority, a personal dose or a universal treatment course.
- Receptor results and the purpose of treatment matter: adjuvant care, advanced cancer and prevention are different settings.
- Bone health, cholesterol and troublesome side effects need an agreed review plan.
- Tell the team about every hormonal medicine, supplement and possible pregnancy.
- Sudden chest pain, stroke symptoms or serious allergic symptoms need emergency help.
- English community prescription items describe use, not individual benefit or worldwide popularity.
Table of contents
- Evidence summary
- What anastrozole is and why receptor results matter
- How aromatase inhibition differs from hormone replacement
- Treatment after surgery, advanced disease and prevention
- Bone support, menopausal symptoms and supplements
- What prescribing counts and the IBIS-II trial establish
- Side effects and symptoms that need urgent help
- Tamoxifen, oestrogen products and other interactions
- Pregnancy, breastfeeding and suitability checks
- Taking tablets, missed doses and treatment changes
- Animal findings and the commercial funding boundary
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Identity and receptor context | NHS and NCI educational originals. | Contributor/trial receipts unclosed. | Attributed care descriptions; no comparative benefit estimate. |
| Prevention licensing | Dated MHRA UK announcement. | Industry-fee/public regulator routes. | Postmenopausal moderate/high-risk scope; not universal eligibility. |
| Bone and interaction safety | NHS care and UK product information. | Unclosed trial receipts; commercial label. | No personal monitoring or replacement regimen. |
| IBIS-II prevention research | Original long-term abstract/design. | AstraZeneca/Sanofi plus named public/charity funds. | Tier 4/D efficacy excluded. |
| Use volume | England FY2025/26 chemical workbook. | Agency finance separately traced. | Prescription items only; no efficacy or global rank. |
| Complementary products | Dated cancer-care safety education. | NCCIH public/gift routes; product interests unclosed. | No independently established anastrozole-adjunct benefit here. |
What anastrozole is and why receptor results matter
Anastrozole is supplied as a prescription tablet. Its intended use is hormone-dependent disease rather than every breast cancer. Prescription context.
ER and PR mean oestrogen and progesterone receptors. Testing tissue from biopsy or surgery identifies hormone receptor status; HER2 is a different marker. Receptor status may change, so selected recurrent disease needs repeat testing. Tumour biomarker distinctions.
Keep the pathology report and the reason for the prescription available when discussing care. A familiar medicine name does not replace the actual receptor result, disease stage or treatment purpose. Someone offered prevention may not have a cancer diagnosis at all.
How aromatase inhibition differs from hormone replacement
Anastrozole reversibly inhibits aromatase enzyme activity, reducing oestrogen production. This is an endocrine anticancer approach, not a drug that supplies oestrogen. Drug mechanism.
NCI distinguishes cancer endocrine care from HRT. Before menopause, aromatase inhibitors require ovarian suppression; men treated with them for advanced breast cancer also receive a GnRH agonist. Class-level specialist context.
UK Arimidex advises against premenopausal use; LHRH-combination data are absent. Its licence differs from specialist class descriptions. UK product boundary.
Treatment after surgery, advanced disease and prevention
The NCI drug page lists US treatment contexts including postmenopausal early hormone-receptor-positive cancer, selected advanced disease and progression after tamoxifen. It is an educational summary, not every possible treatment sequence. US approved cancer-use context.
Endocrine care includes adjuvant treatment after surgery and selected recurrent/advanced disease, sometimes alongside targeted medicines. Different treatment settings.
The MHRA announced a UK prevention authorization on 6 November 2023 for postmenopausal women at moderate or high risk. Prevention is not proof someone already has cancer, and UK authorization is not a worldwide approval. Dated prevention indication.
For prevention, the current UK label requires cardiovascular-risk consideration before starting and review of new or worsening hypertension, high cholesterol or cardiovascular problems during treatment. Prevention-specific safety caution.
Ask the prescribing service to record which setting applies and what follow-up it has arranged. Do not borrow a relative’s course, copy an advanced-cancer combination into prevention or substitute a tablet for the planned breast assessments. This guide provides no risk-score threshold or personal eligibility decision.
Bone support, menopausal symptoms and supplements
NHS guidance describes bone-density assessment, cholesterol monitoring and clinician-selected bone protection. Exercise and diet advice belong within that plan; there is no single scan calendar or automatic bone medicine for everyone here. Long-term review.
Osteoporosis care considers fracture history and other risk factors as well as bone density. The team may review dietary calcium/vitamin D and whether supplementation is needed. General osteoporosis advice to use hormone replacement is not transferred to anastrozole care. Risk-led bone support.
Discuss complementary products with the cancer team; they should not replace or delay cancer care. This safety principle does not establish that a menopause blend, vitamin or “natural aromatase inhibitor” improves anastrozole outcomes. Complementary-care boundary.
A supplement label and a claim about hormones are not a substitute for the prescribing service’s review. Keep the ingredients, strength and brand with the medicine list so the pharmacist can evaluate the actual product.
What prescribing counts and the IBIS-II trial establish
The original England FY2025/26 chemical-substance workbook records 511,730 anastrozole prescription items, BNF code 0803041B0. Actual row 1023.
PCA covers community dispensing in England. Release scope.
Hospital-issued prescriptions dispensed in the community are included; hospital dispensary supplies, private and prison dispensing are excluded. The indication is not recorded. Dispensing coverage. Items are not unique patients, swallowed doses or a worldwide cancer-use ranking.
The original IBIS-II long-term abstract describes a randomized placebo-controlled prevention trial in higher-risk postmenopausal women. It explicitly lists AstraZeneca and Sanofi Aventis alongside Cancer Research UK, Australian NHMRC and Breast Cancer Research Foundation funding. Efficacy is excluded from the independent verdict. Original design and funding.
A medicine’s dispensing volume, licensed role and a trial’s independently established comparative benefit are different questions. The reviewed institutional descriptions do not resolve every original trial’s financing or author interests. No best-brand, recurrence percentage or survival estimate is supplied.
Side effects and symptoms that need urgent help
Hot flushes, sleep difficulty, tiredness, low mood, joint aches and vaginal dryness can occur. Discuss troublesome symptoms or new/persistent vaginal bleeding with the team; a recommended moisturiser may help dryness. Selected side-effect advice.
Get emergency help for sudden chest pain, facial droop or speech difficulty, or sudden mouth/throat swelling, breathing difficulty or collapse. Seek urgent medical advice now for painful/swollen tendons or joints, jaundice, or marked thirst and increased urination with nausea. Urgent warning signs.
Do not drive or operate machinery when tired or dizzy. Driving precaution.
Keep the packet and current medicine list accessible for assessment. Tell the team when symptoms started and how they affect daily activities; do not assume every new symptom is an expected treatment effect.
Tamoxifen, oestrogen products and other interactions
UK information discourages concurrent tamoxifen/oestrogen treatment; a prescribed sequential switch is different. Specific co-use distinction.
HRT and other oestrogen-containing products need review because they can oppose the intended hormonal effect. NHS advice also cautions against menopause herbal remedies and says other complementary products lack adequate interaction information. Hormonal and supplement checks.
This is not a blanket ban on every treatment for menopausal symptoms. Ask the oncology team before starting any hormonal product, including a local vaginal preparation, and discuss nonhormonal options. A prescription from another service needs to be reconciled with the cancer-treatment list.
Do not stop another important medicine to solve a suspected interaction yourself. Give the pharmacist the full list, including occasional medicines and products bought without a prescription.
Pregnancy, breastfeeding and suitability checks
Disclose allergies, ongoing periods, severe kidney/liver problems and brittle bones before treatment. These are suitability-review issues rather than an internet eligibility checklist. Conditions to disclose.
Anastrozole is not recommended during pregnancy or breastfeeding. Possible pregnancy needs prompt contact with the doctor; returning periods require review and reliable contraception. Pregnancy and menstrual precautions.
Do not infer contraception or feeding safety from having previously been told you were postmenopausal. The team needs the current circumstances and can coordinate advice. This article provides no contraceptive interval, breastfeeding clearance or fertility-treatment protocol.
Report problems with the actual tablet’s ingredients to the pharmacist. A product-specific excipient restriction does not justify banning the medicine for every food intolerance or assuming all generic packets have identical ingredients.
Taking tablets, missed doses and treatment changes
NHS instructions say to swallow tablets whole, with or without food. A missed dose is skipped rather than doubled. Follow the supplied packet and prescription; this guide does not assign the strength or schedule. Tablet and missed-dose instructions.
Taking more than prescribed and feeling unwell needs urgent NHS 111 advice; outside the UK use the local urgent/poison service. Keep the packet for the service and do not devise a home antidote. Excess-dose advice.
Do not stop or take a treatment break without discussing it with the specialist; alternatives or an agreed break can be considered when side effects are troublesome. Clinician-agreed changes.
At dispensing, confirm the exact strength, formulation and responsible prescriber. At follow-up, record medicine changes and the next review. Treatment duration and any switch depend on the agreed clinical purpose; no universal multi-year course or stopping calendar is supplied.
Animal findings and the commercial funding boundary
Animal reproductive/tumour findings do not establish human pregnancy safety, cancer rates or benefit. Preclinical boundary.
AstraZeneca’s own 2025 statements distinguish product sales, alliance receipts and collaboration revenue, and disclose borrowing routes. Selected original financial notes Company filings report control through AstraZeneca Intermediate Holdings Ltd to AstraZeneca PLC. Immediate parent Reported parent control.
These records identify commercial incentives. They do not establish the payment behind every clinical page, every historical trial or every generic supplier worldwide. A regulatory warning can be useful for safety while a seller-produced efficacy claim remains excluded from the independent verdict.
This review uses named evidence roles rather than treating an academic affiliation, charity contribution or government-hosted summary as automatic financial clearance. The clinical plan should be discussed with the qualified team responsible for care.
Funding and source roles
Research funding at a glance
29 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: anastrozole overview | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: anastrozole questions | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: anastrozole side effects | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: anastrozole interactions | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: pregnancy and breastfeeding | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: taking anastrozole | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NHS: anastrozole suitability | National policy below; exact page, contributor and source-trial payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | B, provisional — 6 March 2024, due March 2027. Clinical accountability supports practical accuracy; no independently cleared comparative benefit. |
| NCI: anastrozole | Separate appropriations/gift originals below; no named medical byline or complete page/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational clinical context, provisional. | C, provisional — 20 December 2024. Public clinical responsibility favors accuracy; supporting trials and contributor interests remain unclosed. |
| NCI: breast endocrine therapy | Separate appropriations/gift originals below; no named medical byline or complete page/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational clinical context, provisional. | C, provisional — 23 September 2026. Public clinical responsibility favors accuracy; supporting trials and contributor interests remain unclosed. |
| NCI: breast biomarkers | Separate appropriations/gift originals below; no named medical byline or complete page/trial receipts verified. | United States; NCI, Bethesda, Maryland. | Tier 2 educational clinical context, provisional. | C, provisional — 2 December 2025. Public clinical responsibility favors accuracy; supporting trials and contributor interests remain unclosed. |
| NHS: osteoporosis care | National policy below; underlying-study and page payments unclosed. | United Kingdom; national website. | Tier 2 clinical context, provisional. | C, provisional — 13 October 2022; October 2025 deadline passed. Care accountability; no hormone replacement or universal supplement regimen transferred. |
| NCCIH: complementary cancer care | Public/gift routes below; White, Olaku, King, Sansevere and Shurtleff credited; complete personal/page interests unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 2 educational safety context, provisional. | C, provisional — October 2021 update. Public health accountability; no anastrozole-adjunct efficacy or blanket product safety established. |
| MHRA: UK prevention authorization | Separate industry-fee/public routes below; Accord Healthcare Ltd named applicant, not a proven payer for this page. | United Kingdom; MHRA. | Tier 3 regulatory context with industry-fee route. | C, provisional — 6 November 2023. Licensing accountability; trial benefit language excluded and individual prevention eligibility not settled. |
| AstraZeneca: Arimidex UK information | Commercial holder; parent control and own revenue/borrowing records separately traced below. | United Kingdom; AstraZeneca UK Ltd, Cambridge. | Tier 4 seller material; efficacy excluded. | D for independence — text 12 August 2026, emc 27 August 2026. Regulatory safety duties coexist with sales interests; no independent outcome inference. |
| IBIS-II: original long-term abstract | Cancer Research UK, Australian NHMRC, Breast Cancer Research Foundation, Sanofi Aventis and AstraZeneca explicitly listed. | International trial; London author affiliations; every funder headquarters unverified here. | Tier 4 commercially co-funded project; finance/method role only. | D for independence — online December 2019, print January 2020. Actual abstract read; full text and complete author declarations not retrieved. |
| AstraZeneca: 2025 financial statements | Medicine product sales; separate alliance profit/revenue/royalty receipts and collaboration licensing/milestones. Bonds, bank facilities and leases are financing routes. | United Kingdom; multinational AstraZeneca group. | Tier 4 seller financial report; financial-only. | D for independence — actual 79-page original, selected revenue/borrowing notes read. Accounting scrutiny supports money tracing; product-specific receipts/backers unclosed. |
| AstraZeneca UK: reported control | AstraZeneca Intermediate Holdings Ltd: at least 75% share/voting control and director-appointment rights, notified 6 April 2016. | England company 03674842; Cambridge registered address. | Tier 3 company-filed control disclosure, provisional. | C, provisional — actual current PSC body read. Legal disclosure incentives; registry does not verify filed accuracy or all beneficial interests. |
| AstraZeneca intermediate parent: control | AstraZeneca PLC: at least 75% share/voting control and director-appointment rights; no precise stake or full shareholder ledger inferred. | England company 06442028; Cambridge registered address. | Tier 3 company-filed control disclosure, provisional. | C, provisional — actual current PSC body read. Statutory disclosure favors accuracy; no trial/page allocation or every investor traced. |
| NCI: enacted budget | Congressional appropriations through NIH/HHS; enacted fiscal funding distinguished from forward requests. | United States; federal NCI, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — updated 14 May 2026, actual body read. Public budget scrutiny supports accuracy; complete page and trial allocations unclosed. |
| NCI: Gift Fund and address | Voluntary Gift Fund contributions and Breast Cancer Research Stamp route; research designations/company-name field do not establish named page sponsorship. | United States; 9000 Rockville Pike, Bethesda, Maryland 20892. | Tier 3 institutional financial self-report. | B, provisional — 27 August 2025, actual body read. Disclosure/accountability support money tracing; accepted donor receipts and allocation unclosed. |
| NHSBSA: England PCA 2025/26 | Separate agency accounts below; PCA staff/page allocation unclosed. | United Kingdom; England community dispensing. | Tier 2 administrative statistics, provisional. | B, provisional — 4 June 2026. Reimbursement/statistical accountability; no clinical indication or efficacy inference. |
| NHSBSA: original chemical workbook | Same separately documented agency routes; supplier sponsorship not inferred. | United Kingdom; England. | Tier 2 administrative data, provisional. | B, provisional — actual Chemical_Substances row 1023 checked. Items are not patients, doses, adherence, OTC or worldwide use. |
| NHSBSA: PCA methodology | Same documented agency routes; analytic contracts unclosed. | United Kingdom; England. | Tier 2 methods disclosure, provisional. | B, provisional — June 2026 scope/limitations selected. Administrative checking favors totals; no cancer-specific indication ranking established. |
| NHSBSA: accounts 2025/26 | Parliamentary DHSC funding; separate full-cost service charges/public repayment work and DHSC student support. NHS SBS investment noted; complete co-ownership unclosed. | United Kingdom; Stella House, Goldcrest Way, Newburn Riverside, Newcastle upon Tyne NE15 8NY. | Tier 3 institutional financial report. | B, provisional — actual 163-page original, selected pages 132–133/143 and address read. Statutory accounting aids reliability; PCA staff/page allocations remain unassigned. |
| NHS national content/funding policy | DHSC funding; no advertising/corporate sponsorship. Staff/external contributors must disclose interests; full named receipts are not published here. | United Kingdom; national website, separate from provider trusts. | Tier 3 financial/editorial self-report. | B, provisional — 14 October 2022; October 2025 review deadline passed. Public accountability favors accuracy; policy is not current provider accounts or trial clearance. |
| MHRA: accounts 2025/26 | Most running costs from statutory industry fees/non-statutory goods/services; separate DHSC funding. Conflict safeguards described; no alert-specific payer assigned. | United Kingdom; DHSC executive agency. | Tier 3 institutional financial report. | B, provisional — actual 186-page original, funding section and financial statements selected. Statutory audit supports money tracing; regulated-industry and access incentives remain. |
| MHRA: official contact/identity | Industry/public routes documented in separate accounts; complete board/contractor interests unclosed. | United Kingdom; 10 South Colonnade, London E14 4PU. | Tier 3 institutional identity self-report. | B, provisional — actual government contact body read. Official address is reliable identity evidence, not proof of independent efficacy. |
| NCCIH: appropriations history | Enacted congressional appropriations reported through FY2024; no FY2026 request treated as enacted or page allocation inferred. | United States; 9000 Rockville Pike, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual dated fiscal entries read. Public budget scrutiny favors accuracy; complete current receipts and disease-page allocation unclosed. |
| NCCIH: separate Gift Fund route | Authorized voluntary donations/bequests; conditional research-area or unconditional gifts separate from appropriations. Accepted donor receipts unclosed. | United States; NIH/HHS, Bethesda, Maryland. | Tier 3 institutional financial self-report. | B, provisional — actual authority/process read. Disclosure and public accountability favor accuracy; permitted gifts do not establish corporate payment for the safety page. |
Frequently asked questions
Is anastrozole a type of chemotherapy? It is endocrine treatment: an aromatase inhibitor that reduces oestrogen production. It is not menopausal hormone replacement. Medicine identity.
Can it be taken before menopause? This needs specialist interpretation of ovarian function and the actual licence; anastrozole alone is not a self-selected premenopausal plan. Specialist class context.
What if my periods return or pregnancy is possible? Contact the treating doctor promptly and discuss contraception; do not assume pregnancy is impossible. Current-situation review.
Can I take HRT or a menopause supplement? Ask the cancer team first. Hormonal products and menopause remedies need review; inadequate interaction evidence is not proof of safety. Specific product checks.
Does every user need the same bone supplement? No. Diet, fracture risk and bone assessment inform care; no automatic supplement regimen is established here. Individual bone-care context.
Does high prescribing volume prove it is best? No. English prescription items cannot compare individual benefit, brand quality or worldwide cancer use.
Sources and funding notes
The clinical roles are geographically bounded. US class-level specialist descriptions do not override UK product licensing. The original IBIS-II abstract was actually read; full text and complete personal declarations were not retrieved, so commercially co-funded outcomes are excluded. The current licence holder and reported parent control are separately traced, without extending that chain to all generics. Clinical-page payments, complete named reviewer interests and supporting-trial finances remain unclosed. The dated NHS osteoporosis/policy deadlines have passed; only narrowly identified advice is used. No personal dose, universal scan interval, prevention risk threshold, treatment course, supplement regimen or independent comparative benefit is supplied.
- NHS: anastrozole overview — Prescription identity and selected uses.
- NHS: anastrozole questions — Bone/cholesterol review and agreed changes.
- NHS: anastrozole side effects — Selected symptoms and emergency signs.
- NHS: anastrozole interactions — Hormonal products and supplement review.
- NHS: pregnancy and breastfeeding — Pregnancy concern, periods and contraception review.
- NHS: taking anastrozole — Tablet handling, missed dose and excess-dose advice.
- NHS: anastrozole suitability — Conditions to disclose before treatment.
- NCI: anastrozole — Enzyme activity and US cancer-use context.
- NCI: breast endocrine therapy — Class-level menopausal/ovarian and treatment contexts.
- NCI: breast biomarkers — Tissue receptor/HER2 distinctions.
- NHS: osteoporosis care — Diet/risk-led bone support only.
- NCCIH: complementary cancer care — Disclosure and non-replacement safety only.
- MHRA: UK prevention authorization — Dated indication/applicant context only.
- AstraZeneca: Arimidex UK information — Product-specific prevention safety, scope and interactions.
- IBIS-II: original long-term abstract — Trial design/funding only; efficacy excluded.
- AstraZeneca: 2025 financial statements — Company revenue/financing routes only.
- AstraZeneca UK: reported control — Immediate reported parent, not exact ownership.
- AstraZeneca intermediate parent: control — Reported ultimate corporate control band.
- NCI: enacted budget — Institutional appropriations, not drug-page funding.
- NCI: Gift Fund and address — Separate gift authority/routes only.
- NHSBSA: England PCA 2025/26 — Publication and community setting.
- NHSBSA: original chemical workbook — Anastrozole item count/code only.
- NHSBSA: PCA methodology — Dispensing coverage and indication limits.
- NHSBSA: accounts 2025/26 — Institutional funding/HQ trace only.
- NHS national content/funding policy — Website funding and editorial safeguards only.
- MHRA: accounts 2025/26 — Regulator-specific funding only.
- MHRA: official contact/identity — Jurisdiction and office only.
- NCCIH: appropriations history — Congressional route and institutional address only.
- NCCIH: separate Gift Fund route — Gift authority, not a named page sponsor.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.